N5

Farrel, Joseph, and Chicu, Mark. (2018). "Pharmaceutical Patents and Pay-for-Delay: Actavis (2013)" in John Kwoka and Lawrence White (eds), Antitrust Revolution: Economics, Competition and Policy, 7th edition, Oxford University Press, Case 15.

1a) Why did Solvay and the generic producer have an incentive to encourage a delay?

2b) What did Solvay do to protect the market dominance of AndroGel? How did Solvay do that? What was the FTC's responses?